Brazikumab ( AMG139, previously known as AMG139) continues a promising therapeutic candidate targeting IL-17F . Recent trial data from the phase 3 IMMU-NYMPH3 trial evaluating its benefit in patients with significant psoriatic arthritis have shown variable outcomes . While initial data suggested … Read More